KLOW Blend Overview

The KLOW Blend combines GHK-Cu, BPC-157, TB-500, and KPV into a single formulation studied for its potential influence on cellular repair and systemic regulation. In laboratory and preclinical models, these peptides have been investigated for their effects on tissue remodeling, angiogenesis, inflammatory modulation, and extracellular matrix activity. Together, they provide a platform for exploring synergistic pathways in regeneration, immune signaling, and vascular biology.

Pickart L. & Margolina A. 2018

History

The KLOW Blend draws on several decades of peptide research, bringing together compounds that have been investigated in diverse experimental contexts. GHK-Cu, first identified in human plasma in the 1970s, has been studied for its potential roles in gene expression and wound repair models. BPC-157, synthesized in the 1990s as a gastric protein fragment analog, has been explored in relation to angiogenic and reparative processes. TB-500, a synthetic fragment of thymosin beta-4 originating from thymus peptide research of the 1960s, has been examined in studies of angiogenesis and cellular migration. KPV, a C-terminal fragment of α-MSH, has been evaluated for its anti-inflammatory and immunomodulatory activity in research settings. Collectively, these peptides represent areas of ongoing scientific investigation into regenerative biology, vascular pathways, and immune signaling. The KLOW Blend is intended for research use only and is not for human or animal therapeutic applications.

Maquart F.X. et al. 1988

GHK-Cu Structure

CAS #: 49557-75-7

Molecular Formula: C₁₄H₂₄CuN₆O₄

Molecular Weight: 340.9 g/mol

PubChem ID: 5311476

BPC-157 Structure

CAS #: 137525-51-0

Molecular Formula: C₁₄H₂₄CuN₆O₄

Molecular Weight: 340.9 g/mol

PubChem ID: 5311476

TB-500 Structure

CAS #: 77591-33-4

Molecular Formula: C₂₁₂H₃₅₀N₅₆O₇₈S

Molecular Weight: 4963.5 g/mol

PubChem ID: 16132321

KPV Structure

CAS #: 3061-91-6

Formula: C₁₆H₂₈N₆O₅

Molecular Weight: 388.4 g/mol

PubChem ID: 16129619

Research Findings

The KLOW Blend, which combines GHK-Cu, BPC-157, TB-500, and KPV, has been studied in structural, vascular, dermatological, and systemic models. Research highlights activity in collagen formation, extracellular matrix remodeling, angiogenesis, wound closure, and inflammation modulation. The inclusion of KPV further supports immune regulation and anti-inflammatory pathways, expanding the experimental scope of this blend in preclinical settings.

Key Areas of Research:

• Structural: collagen, matrix, connective tissue

• Vascular: angiogenesis, nitric oxide, remodeling

• Dermatological: wound closure, skin, hair growth

• Systemic: inflammation, immune balance, recovery

Together, these findings suggest broad experimental potential for the KLOW Blend across multiple biological pathways. By combining structural support, vascular and dermatological activity, and immune regulation, the KLOW Blend provides a versatile platform for research into regeneration, tissue repair, and systemic resilience in laboratory models.

Sikiric P. et al., 2020

References

Pickart L. et al. (2015). GHK-Cu and regulation of multiple biological processes in aging and repair. BioMed Res Int.

Sikiric P. et al. (1993). A new gastric peptide, BPC-157, characterized and synthesized. Peptides, 14(1):127–131.

Goldstein A.L. et al. (2005). Thymosin beta-4 and tissue regeneration: potential mechanisms of action. Ann N Y Acad Sci.

Maquart F.X. et al. (1988). Stimulation of collagen synthesis by the tripeptide GHK in fibroblast cultures. FEBS Lett, 238(2):343–346.

Japjec M. et al. (2021). BPC-157 and tendon/ligament structural integrity in experimental models. Int J Mol Sci, 22(17):9397.

Smart N. et al. (2007). Thymosin beta-4 induces progenitor mobilization and neovascularization. Nature, 445(7124):177–182.

Seiwert S. et al. (2018). Angiogenic activity and NO-system modulation by BPC-157 in laboratory models. J Vasc Res, 55(3):155–163.

Philp D. et al. (2003). Thymosin beta-4 promotes dermal wound healing. J Invest Dermatol, 121(4):694–701. 

Hsieh M.J. et al. (2014). Pro-angiogenic and reparative effects of BPC-157 in preclinical models. J Mol Med, 92(5):483–495.

Moss J. et al. (2020). Anti-inflammatory properties of the tripeptide KPV in epithelial and systemic models. Int J Pept Res Ther, 26:1037–1046.

Kang E.A. et al. (2020). BPC-157 protective effects on liver, kidney, and lung in ischemia–reperfusion injury. Int J Mol Sci, 21(12):4232.